Zymeworks

About Zymeworks

Zymeworks Inc. is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of multifunctional biotherapeutics for the treatment of cancer and other serious diseases. Its lead product candidates include zanidatamab, a HER2-targeted therapy in multiple phases of clinical trials, and zanidatamab zovodotin, an antibody-drug conjugate for advanced HER2-expressing tumors. Zymeworks also maintains a pipeline of preclinical and discovery-stage oncology programs, leveraging advanced antibody and biotherapeutic engineering platforms.